About this series:
CEOLIVE is an ongoing video interview series that features Officers, Directors and other key executives from U.S. publicly traded companies addressing topics related to the company's business performance and strategy. The interviews are not intended to provide the first announcement of material information or developments about the company. Instead, they will discuss matters previously announced through other channels or that are not themselves considered material information under securities laws, even though the matters may be important to shareholders.
Your next episode will begin in seconds...
About this episode
Dec 3, 2010
08:59
News & Politics
Interview with Mr. Jeffrey Davis, President & CEO of Access Pharmaceuticals, Inc. (OTCBB:ACCP).About Access: ;Access Pharmaceuticals, Inc. is an eme...
Interview with Mr. Jeffrey Davis, President & CEO of Access Pharmaceuticals, Inc. (OTCBB:ACCP).About Access: ;Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access' products include MuGard™ (www.mugard.com), for the management of patients with mucositis, ProLindac™, currently in Phase II clinical testing of patients with ovarian cancer, and Thiarabine, a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers. The company also has additional advanced drug-delivery technologies, including CobaCyte™-mediated targeted delivery and CobOral-oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism. For additional information on Access Pharmaceuticals, please visit our website at
Less
